US EditionPortal Access Closes $7M Series A Financing
- PorTal Access, Inc. Secured $7 million in funding through a fully subscribed initial Series A investment round in Miami on May 27, 2025, aimed at further development of its Flexi-Port SLF-TANL device.
- The funding follows strong clinical demand and physician enthusiasm for the device, which aims to reduce complications in chemo port placement and address delays in treatment.
- The Flexi-Port SLF-TANL features innovative self-tunneling technology enabling safe, minimally invasive bedside or outpatient placement, simplifying vascular access for cancer patients.
- Matthew Ostroff, a pioneer in bedside vascular access, said the device has "consistently exceeded expectations," while Angela Dotson highlighted unprecedented physician enthusiasm and $6 million invested by doctors.
- PorTal Access plans to use the funds to support regulatory activities, including a July 2025 510 FDA submission, with a limited U.S. Market launch expected by early 2026.
40 Articles
40 Articles
Chatham Star Tribune
Portal Access, Inc. Announces the closing of $7 Million Series A Financing Round to Support FDA Approval and Limited Market Launch of Next-Generation Chemotherapy Port
MIAMI, May 27, 2025 /PRNewswire/ -- Portal Access, Inc., a medical device start-up company pioneering next-generation advanced vascular access solutions for oncology, announced the successful closing of a $7 million Series A financing round today. The round was fully subscribed,…
With doctors’ support, PorTal Access raises $7M to launch novel medical device for cancer patients - Refresh Miami
PorTal Access, a pioneering medical device company on a mission to improve vascular access solutions for cancer patients, has announced it has secured a $7 million Series A round. The Miami-based company reports that $6 million of the round is from U.S.-based physicians such as oncologists, interventional radiologists and vascular surgeons. The funding will help support the company’s regulatory path ahead: the submission of a 510(k) application …
Portal Access Closes $7M Series A Financing
Portal Access, a Miami, FL-based medical device company, raised $7M in Series A funding. Backers were not disclosed. Led by CEO and Founder Dr. Michael Tal, PorTal Access provides designing solutions to reduce complications currently associated with chemo port placement while offering a safe and minimally invasive option for bedside or in an outpatient setting. By […] The post Portal Access Closes $7M Series A Financing appeared first on FinSMEs.
Coverage Details
Bias Distribution
- 61% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
